SCHEMBL4599034

SCHEMBL4599034

OCCNCc1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.56
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MPO P05164 2/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
PDCD1 Q15116 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
PLA2G1B P04054 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8326406 0.96 CHRM2 (0.66) CHRM2L3MBTL1LMNASMN1; SMN2MPO
SCHEMBL8019471 0.91 CHRM2 (0.82) CHRM2L3MBTL1SMN1; SMN2MPOALDH1A1
SCHEMBL1625535 0.89 SMN1; SMN2 (0.64) CHRM2SMN1; SMN2ALDH1A1KDM4EPDCD1
SCHEMBL4262728 0.88 CHRM2 (0.71) CHRM2L3MBTL1LMNAMPOALDH1A1
Hydrochloric Acid SCHEMBL9672905 0.86 CHRM2 (0.69) CHRM2L3MBTL1LMNAMPOALDH1A1
SCHEMBL8328507 0.86 CHRM2 (0.75) CHRM2L3MBTL1LMNAMPOALDH1A1
SCHEMBL8328363 0.84 CHRM2 (0.79) CHRM2L3MBTL1LMNAMPOALDH1A1
SCHEMBL26139696 0.82 DPP7 (0.61) CHRM2L3MBTL1LMNAMPOALDH1A1
SCHEMBL8330901 0.81 CHRM2 (0.53) CHRM2L3MBTL1LMNAMPOALDH1A1
SCHEMBL1796909 0.81 LMNA (0.77) CHRM2L3MBTL1LMNAMPOALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108341788-A A kind of mosapride citrate intermediate and purposes 鲁南制药集团股份有限公司 2018-07-31 CN claimed
CN-108129414-A A kind of preparation method of mosapride citrate intermediate 鲁南制药集团股份有限公司 2018-06-08 CN claimed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 US disclosed
CN-112225708-B Preparation method of mosapride intermediate 上海翰森生物医药科技有限公司 2021-04-09 CN disclosed
CN-112225708-A Preparation method of mosapride intermediate 上海翰森生物医药科技有限公司 2021-01-15 CN disclosed
CN-108129414-B Preparation method of mosapride citrate intermediate 鲁南制药集团股份有限公司 2020-12-08 CN disclosed
CN-108341788-A A kind of mosapride citrate intermediate and purposes 鲁南制药集团股份有限公司 2018-07-31 CN disclosed
CN-108129414-A A kind of preparation method of mosapride citrate intermediate 鲁南制药集团股份有限公司 2018-06-08 CN disclosed
EP-2928890-B1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY CHIESI FARM SPA (IT) 2018-02-28 EP disclosed
EP-2804868-B1 PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2017-04-12 EP disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed
EP-1515958-A2 PROCESS FOR THE SYNTHESIS OF MOSAPRIDE RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2005-03-23 EP disclosed
WO-2003106440-A2 PROCESS FOR THE SYNTHESIS OF A BENZAMIDE DERIVATIVE Richter Gedeon Vegyészeti Gyár Rt. (HU) 2003-12-24 WO disclosed
EP-0760368-B1 PYRIMIDINE DERIVATIVES NISSHIN FLOUR MILLING CO (JP) 1999-07-28 EP disclosed
US-5736550-A TREATMENT OF GASTROINTESTINAL TRACT DISORDERS NISSHIN FLOUR MILLING CO., LTD. (JP) 1998-04-07 US disclosed
EP-0760368-A1 NOVEL PYRIMIDINE DERIVATIVE NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-03-05 EP disclosed
EP-0243959-B1 SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 1992-08-19 EP disclosed
US-4870074-A Substituted benzamide derivatives, for enhancing gastrointestinal motility DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1989-09-26 US disclosed
EP-0243959-A1 Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same Dainippon Pharmaceutical Co., Ltd. (JP) 1987-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 CHRM2 2132/4885L3MBTL1 1690/4885LMNA 1148/4885
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 CHRM2 31/4885L3MBTL1 1685/4885LMNA 4744/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 CHRM2 1854/4885L3MBTL1 1923/4885LMNA 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.